Colorectal Cancer Molecular Diagnostics Market Report 2026

The colorectal cancer molecular diagnostics market size has grown strongly in recent years. It will grow from $2.78 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing colorectal cancer incidence rates, expansion of diagnostic laboratory infrastructure, rising adoption of molecular testing protocols, improved awareness of early screening, growing use of precision medicine approaches.

The colorectal cancer molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for minimally invasive diagnostics, expansion of genomic testing programs, growing integration of ai in cancer diagnostics, increasing focus on treatment response monitoring. Major trends in the forecast period include increasing adoption of molecular biomarker testing, rising use of pcr and sequencing technologies, growing demand for personalized oncology diagnostics, expansion of companion diagnostic development, enhanced focus on early cancer detection.

The increasing prevalence of colorectal cancer is expected to drive the growth of the colorectal cancer molecular diagnostics market in the coming years. Colorectal cancer is a condition that affects the colon or rectum, which are key components of the digestive system, and occurs when abnormal cells in these regions grow uncontrollably and form tumors. A rise in colorectal cancer cases directly increases the need for advanced molecular diagnostic solutions to support early detection, diagnosis, and treatment decision-making. For example, in March 2023, according to the American Cancer Society, a US-based nationwide voluntary health organization focused on cancer prevention and control, approximately 153,020 individuals were projected to be diagnosed with colorectal cancer, with around 52,550 deaths expected. Of these cases, about 19,550 diagnoses and 3,750 deaths were anticipated among individuals younger than 50 years. As a result, the growing burden of colorectal cancer is contributing to the expansion of the colorectal cancer molecular diagnostics market.

Major companies operating in the colorectal cancer molecular diagnostics market are increasingly concentrating on the development of innovative solutions such as blood-based liquid biopsy screening tests to address the rising demand for non-invasive early detection methods. These approaches aim to improve patient compliance compared with colonoscopy and enable broader population screening as clinical guidelines and reimbursement frameworks evolve. A liquid biopsy is a blood-based test that identifies tumor-derived biomarkers from a simple blood draw and is characterized by minimal invasiveness, suitability for screening asymptomatic individuals, and high molecular sensitivity. For instance, in July 2024, Guardant Health, a US-based precision oncology company, launched Shield, a blood-based colorectal cancer screening test that received approval from the US Food and Drug Administration as a primary screening option for average-risk adults aged 45 and older. Shield is a multi-marker blood assay designed to analyze circulating tumor signals to identify individuals likely to have colorectal cancer. The test was developed and validated through the large ECLIPSE clinical program and demonstrated sufficient sensitivity and specificity to achieve FDA primary screening designation. Its functionality combines sequencing technologies with proprietary bioinformatic classifiers to detect methylation and other tumor-derived signals in plasma. Key features include the convenience of a single blood draw, the potential to increase screening participation, and a pathway toward Medicare coverage. The test is intended for population-level screening and for guiding referrals to diagnostic colonoscopy in positive cases, enabling earlier detection with fewer invasive procedures.

In July 2023, New Day Diagnostics LLC, a US-based medical equipment manufacturing company, acquired the assets of Epigenomics AG for an undisclosed amount. Through this acquisition, New Day Diagnostics expanded its cancer diagnostics portfolio by gaining ownership of intellectual property developed by Epigenomics AG, including Epi ProColon, a screening technology designed for the non-invasive detection of colorectal cancer. Epigenomics AG is a Germany-based company specializing in colorectal cancer molecular diagnostics.

Major companies operating in the colorectal cancer molecular diagnostics market are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

North America was the largest region in the colorectal cancer molecular diagnostics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the colorectal cancer molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the colorectal cancer molecular diagnostics market by increasing costs of imported sequencing instruments, reagents, assay kits, microarrays, and advanced laboratory equipment. Diagnostic laboratories in North America and Europe are most affected due to dependence on global life science suppliers, while Asia-Pacific faces higher costs for exporting diagnostic platforms. These tariffs are increasing testing costs and influencing laboratory procurement strategies. However, they are also supporting local reagent manufacturing, regional instrument assembly, and domestic expansion of molecular diagnostic capabilities.

The colorectal cancer molecular diagnostics market research report is one of a series of new reports that provides colorectal cancer molecular diagnostics market statistics, including colorectal cancer molecular diagnostics industry global market size, regional shares, competitors with a colorectal cancer molecular diagnostics market share, detailed colorectal cancer molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer molecular diagnostics industry. This colorectal cancer molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Colorectal cancer, also referred to as colon cancer or rectal cancer, is a malignant tumor that forms in the colon, which is part of the large intestine, or in the rectum, the final section of the digestive tract before the anus. It originates from the inner lining of these regions of the gastrointestinal system. Colorectal cancer molecular diagnostics involve the use of advanced techniques to detect specific genetic mutations, molecular alterations, and biomarkers that contribute to the development, progression, and treatment response of colorectal cancer.

The primary types of colorectal cancer molecular diagnostics include instruments, reagents, kits, and services. An instrument is a specialized device used to analyze and identify molecular changes, such as genetic mutations, gene expression variations, or specific biomolecules, in biological samples from patients with colorectal cancer. These molecular diagnostic solutions are based on technologies including polymerase chain reaction, sequencing, mass spectrometry, transcription-mediated amplification, chips and microarrays, and isothermal nucleic acid amplification technology. They are used by various end users such as hospitals, ambulatory surgical centers, diagnostic laboratories, and homecare settings.

The colorectal cancer molecular diagnostics market consists of revenues earned by entities by providing diagnostic genetic mutation analysis, biomarker profiling, and epigenetic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The colorectal cancer molecular diagnostics market consists of sales of molecular diagnostic biochips, liquid biopsy kits, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.